FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
NOVATO, Calif., Feb. 14, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Tuesday, February 20, 2018 at 5pm ET to discuss fourth quarter and full year 2017 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 1987066. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
